Irbesartan Bristol Laboratories

Irbesartan, the active ingredient in Irbesartan Bristol Laboratories, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to lower blood pressure and protect kidney function in patients with hypertension, diabetic nephropathy, and heart failure, and is marketed in the European Union.

GNH USA supplies Irbesartan Bristol Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to control blood pressure and related conditions.

Hypertension: reduces systolic and diastolic pressure, lowering the risk of cardiovascular events. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Heart failure: improves cardiac function and reduces hospitalisation rates in patients with reduced ejection fraction.

Irbesartan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Hyperkalaemia - Upper respiratory tract infection - Nausea

Serious or Rare Side Effects: - Angioedema - Acute renal impairment - Hepatic injury - Severe hypotension - Anaphylactic reaction - Pancreatitis

When prescribing Irbesartan, clinicians should observe several safety considerations.

Blood pressure monitoring: check regularly to avoid excessive hypotension. Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. Serum potassium monitoring: watch for hyperkalaemia, especially with potassium‑sparing agents. Pregnancy avoidance: contraindicated in pregnancy due to fetal risk. Hepatic impairment caution: dose may need adjustment in severe liver disease. Store at ambient temperature: keep in the original container, protect from moisture and light.

Irbesartan can interact with several medicines; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase renal risk. - Concurrent ACE inhibitor or ARB therapy: may cause excessive potassium rise and renal dysfunction. - Potassium‑sparing diuretics or supplements: increase risk of hyperkalaemia.

Moderate Interactions (Monitor Closely): - Thiazide or loop diuretics: may enhance antihypertensive effect, monitor blood pressure. - Lithium: Irbesartan can raise lithium levels, monitor for toxicity. - Cyclosporine or tacrolimus: may increase serum creatinine, watch renal function.